The drop has the potential to become the first-ever ocular surface indication for an IG.

The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.

Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.

The award marks the company's fifth consecutive recognition from the program.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

Catch up on the top stories in optometry during the week of May 12-May 16.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

Can a drop of perfluorohexyloctane, known to persist in the tear film, influence the precision of keratometry and ultimately affect surgical planning?

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

Because this year’s session is joint between the AOA and WCO, the session will feature work from members across both groups.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The bill, which passed on May 1, allows for West Virginian ODs to provide certain in-office procedures.

Bausch + Lomb’s propriety Zenlens technology, which includes SmartCurve and Bi-Elevation, apply custom HOA correction to the lens to reduce visual disturbance, blurring, and distortion.

Enhanced scleral lens design and order management platform for practitioners provides exceptional user experience.

The 3200 square-foot unit offers diagnostics, cataract surgery, YAG laser capsulotomy, and post op care.

Digital Twin and VESA can integrate refractive data, topography, biomechanical properties, and even simulate age-related changes in the eye—turning it into a predictive and diagnostic tool for clinicians managing complex conditions like presbyopia.

Valeda met the primary end point in the US LIGHTSIDE III trial, improving the best corrected visual acuity in patients for 24 months of >5 letters or equivalent to 1 line improvement on the eye chart, according to the company.